espite a decline of gonorrhea in the United States during the past two decades, this sexually transmitted disease (STD) remains common in many inner cities, and some rural areas are currently experiencing high rates of infection, z Treatment of gonorrhea involved the almost exclusive use of penicillin and tetracyclines from the 1940s until the mid-1980s, when antibiotic resistance be-came troublesome. 3 Today there are numerous antimicrobial agents at our disposal that are highly active against Neisseria gonorrhoeae, making the choice of treatment more difficult. All of the commercially available fluoroquinolones have proved effective as single-dose therapy of gonorrhea, 4 , s including infections due to penicillinase-producing gonococci, 5 but only ciprofloxacin, ofloxacin, enoxacin, and norfloxacin are among the agents currently recommended by the Centers for Disease Control and Prevention. 6 After initial treatment for gonorrhea, follow-up therapy with an antibiotic regimen effective against possible coexistent infection with Chlamydia trachomatis is recommended. 6 Thus, the ideal antibiotic would be one that is effective against both gonococcal and chlamydial infections.
Grepafloxacin is a new, orally administered fluoroquinolone with excellent in vitro activity against N. gonorrhoeae; it is 4-8 fold more potent than ofloxacin against penicillin-and tetracyclineresistant strains 7 and more active than ofloxacin against C. trachomatis. 8 The drug is concentrated intracellularly, 9 has a long serum half-life (--12 hours) that allows for once-daily dosing, 1 and achieves high therapeutic levels in male and female genital tissue. TM lZ These features indicate that grepafloxacin is a promising agent for treating common STDs.
A recent study has shown that a single 400-mg dose of grepafloxacin was as effective as the same dose of cefixime in the treatment of gonococcal urethritis in men. 13 The purpose of the present multicenter study was to investigate the efficacy and tolerance of grepafloxacin and cefixime in women with uncomplicated gonorrhea.
SUBJECTS AND METHODS
The patients studied were Although not a primary goal of the study, an interesting finding was that a total of 49 patients had positive pretreatment cultures for C. trachomatis. Of these patients, 27 of 31 (87%) given grepafloxaci and 4 of 18 (22%) given cefixime had negative cultures for C. trachomatis at follow-up (P < 0.001). All patients with a confirmed C. trachomatis infection were treated with doxycycline. In all, about half (55%) of the patients in each treatment group who returned for follow-up examination were given a course of doxycycline to cover C. trachomatis. In some cases this was based on pretreatmerit culture results, but other clinics routinely treated all participants at follow-up. In addition, 13% of patients in each group received metronidazole for the treatment of trichomonal infection.
Adverse events that were considered treatment related occurred in 49 patients (62 events) in the grepafloxacin group and 28 patients (34 events) in the cefixime group (P 0.010). All but nine of the events were mild to moderate and resolved spontaneously. One patient in each group experienced severe vaginal discharge (lcukorrhea), which was considered to be drug related. One patient in the cefixime group was treated for a C. trachomatis infection, and another experienced headache and chest pain. In the grepafloxacin-treated group, one patient reported severe nausea and vomiting, and another had severe abdominal pain and diarrhea. The most frequently reported treatment-related events arc presented in Table 3 . Vaginitis was the most common individual treatment-related problem in each group, although when all gastrointestinal events were combined, they were more common overall. The overall incidence of treatmentrelated adverse events was higher in grepafloxacintreated patients, but there was no significant difference in the incidences of individual adverse events between the treatment groups. In addition, none of the changes in laboratory values were considered clinically relevant.
DISCUSSION
This study has shown that a single 400-mg oral dose of grepafloxacin is at least as effective as the same dose of cefixime for treatment of uncomplicated gonorrhea in women. Both drugs were highly effective (99% cure rate) in eradicating N. gonorrhoeae from the cervix, despite the fact that a third of the study patients were infected with penicillinor tetracycline-resistant strains. Sixty-six of 70 (94%) of such isolates were eradicated by grepafloxacin as were 47 of 53 (89%) by cefixime. All As C. trachomatis is frequently present along with N. gonorrhoeae in genital infections, an agent that is effective in eliminating both pathogens would be a significant advance over conventional therapy using two or more antibiotics. Grepafloxacin has greater antigonococcal and antichlamydial activity in vitro than standard agents, 7, 8 and is two to 16 times more active than ceftriaxone and ofloxacin against susceptible, as well as penicillin-and tetracycline-resistant strains of N. gonorrhoeae. 7 Moreover, its activity is considerably greater than that of tetracycline against chlamydia, with some strains of C. trachomatis being up to 128 times more sensitive to grepafloxacin. 19 Such potency, together with a highly bactericidal action on Chlamydia species in vitro, may translate into good clinical efficacy. 18 These data, as well as our initial findings in nongonococcal urethritis and cervicitis clinical trials (in preparation), suggest that grepafloxacin may be useful as therapy for genital infections when both pathogens are present. Consequently, grepafloxacin is a promising new therapeutic agent for common STDs in both males and females.
